DE69230475D1 - Verzögerte Freigabe Matrix für Arzneimittel - Google Patents

Verzögerte Freigabe Matrix für Arzneimittel

Info

Publication number
DE69230475D1
DE69230475D1 DE69230475T DE69230475T DE69230475D1 DE 69230475 D1 DE69230475 D1 DE 69230475D1 DE 69230475 T DE69230475 T DE 69230475T DE 69230475 T DE69230475 T DE 69230475T DE 69230475 D1 DE69230475 D1 DE 69230475D1
Authority
DE
Germany
Prior art keywords
drugs
release matrix
matrix
delayed release
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69230475T
Other languages
English (en)
Other versions
DE69230475T2 (de
Inventor
Thinnayam N Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE69230475D1 publication Critical patent/DE69230475D1/de
Publication of DE69230475T2 publication Critical patent/DE69230475T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69230475T 1991-09-11 1992-04-15 Verzögerte Freigabe Matrix für Arzneimittel Expired - Lifetime DE69230475T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/758,883 US5215758A (en) 1991-09-11 1991-09-11 Controlled release matrix suppository for pharmaceuticals

Publications (2)

Publication Number Publication Date
DE69230475D1 true DE69230475D1 (de) 2000-01-27
DE69230475T2 DE69230475T2 (de) 2000-07-13

Family

ID=25053475

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69215612T Expired - Lifetime DE69215612T2 (de) 1991-09-11 1992-04-15 Verzögerte Freigabe-Matrix für Arzneimittel
DE69230475T Expired - Lifetime DE69230475T2 (de) 1991-09-11 1992-04-15 Verzögerte Freigabe Matrix für Arzneimittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69215612T Expired - Lifetime DE69215612T2 (de) 1991-09-11 1992-04-15 Verzögerte Freigabe-Matrix für Arzneimittel

Country Status (13)

Country Link
US (2) US5215758A (de)
EP (2) EP0698389B1 (de)
JP (2) JP3034125B2 (de)
KR (2) KR100203339B1 (de)
AT (2) ATE145820T1 (de)
AU (1) AU653048B2 (de)
CA (1) CA2065210C (de)
DE (2) DE69215612T2 (de)
DK (2) DK0531611T3 (de)
ES (2) ES2139798T3 (de)
GR (1) GR3022572T3 (de)
IL (2) IL101758A (de)
ZA (1) ZA923417B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
WO1994003159A1 (en) * 1992-07-31 1994-02-17 Daratech Pty. Ltd. Controlled release implants
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554379A (en) * 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
KR970064596A (ko) * 1996-03-21 1997-10-13 이우용 직장투여용 치질치료제 조성물
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
JP3148256B2 (ja) 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
UA53774C2 (uk) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
WO1999032119A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
DK0978285T3 (da) 1998-08-07 2006-03-27 Curis Inc Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
DE60038536T2 (de) * 1999-09-30 2009-06-10 Penwest Pharmaceuticals Co. Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
CA2400578C (en) 2000-02-08 2007-01-02 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6720356B2 (en) * 2001-04-20 2004-04-13 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CN1610551A (zh) * 2001-07-06 2005-04-27 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
DE60230632D1 (de) * 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
EP2243471A1 (de) 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix für die modifizierte Freigabe von aktiven Substanzen
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
EP1545468A4 (de) * 2002-09-20 2007-06-20 Alpharma Inc Opioid-formulierungen mit verz gerter freisetzung und anwendungsverfahren
WO2004047713A2 (en) * 2002-11-26 2004-06-10 Hollenbeck Garry R Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
EP2298303A1 (de) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmazeutische kombinationen von hydrocodon und naltrexon
DE602004026604D1 (de) 2003-09-25 2010-05-27 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070082050A1 (en) * 2005-05-31 2007-04-12 Cherukuri S R Modified release formulations of antihypertensive drugs
KR100730321B1 (ko) 2005-09-30 2007-06-19 한국콜마 주식회사 패치형태의 리프팅용 2제형 화장료 조성물과 이의 제조방법및 사용방법
SE530184C2 (sv) 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
WO2007077551A2 (en) * 2005-12-30 2007-07-12 Mor Research Applications Ltd. Device and method for treating the anal sphincter
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
BRPI0910780A2 (pt) * 2008-07-07 2016-08-09 Euro Celtique Sa uso de antagonistas de opióides para o tratamento da retenção urinária
CN102245176B (zh) * 2008-10-31 2015-05-27 脂质医药有限公司 用作药物的脂肪酸
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
EP2445481B1 (de) 2009-06-18 2017-03-22 Rdd Pharma Ltd. Verfahren und vorrichtungen zur freisetzung von arzneimitteln in körperöffnungen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2011280039B2 (en) 2010-06-30 2014-08-07 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
CN103370058A (zh) 2010-12-22 2013-10-23 普渡制药公司 包覆的抗篡改控制释放剂型
CN107412173A (zh) 2010-12-23 2017-12-01 普渡制药公司 抗篡改固体口服剂型
CN104507947B (zh) 2012-07-16 2017-06-27 罗德科技公司 用于改进的阿片样物质合成的方法
JP6236447B2 (ja) 2012-07-16 2017-11-22 ローズ テクノロジーズ 改善されたオピオイド合成方法
CN102823585B (zh) * 2012-08-28 2014-06-25 中国农业科学院农业环境与可持续发展研究所 一种水溶性农药缓控释制剂及其制备方法
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
WO2014140899A2 (en) 2013-03-15 2014-09-18 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
EP3027622B8 (de) 2013-08-02 2019-06-12 Johnson Matthey Public Limited Company Verfahren zur herstellung von oxymorphon
CN105658205A (zh) * 2013-12-20 2016-06-08 迪斯法国际私人有限责任公司 干灌肠产品
WO2015107472A1 (en) 2014-01-15 2015-07-23 Rhodes Technologies Process for improved oxymorphone synthesis
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPH0684296B2 (ja) * 1987-12-21 1994-10-26 花王株式会社 多層坐剤
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5110605A (en) * 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method

Also Published As

Publication number Publication date
CA2065210A1 (en) 1993-03-12
ES2139798T3 (es) 2000-02-16
US5508043A (en) 1996-04-16
CA2065210C (en) 2000-08-29
ZA923417B (en) 1993-01-27
US5215758A (en) 1993-06-01
DE69230475T2 (de) 2000-07-13
EP0531611A1 (de) 1993-03-17
DK0698389T3 (da) 2000-05-01
AU2107392A (en) 1993-03-18
JP3034125B2 (ja) 2000-04-17
KR930005616A (ko) 1993-04-20
JP3624123B2 (ja) 2005-03-02
KR100225493B1 (en) 1999-10-15
ATE145820T1 (de) 1996-12-15
ES2097826T3 (es) 1997-04-16
ATE187887T1 (de) 2000-01-15
DE69215612D1 (de) 1997-01-16
IL101758A0 (en) 1992-12-30
GR3022572T3 (en) 1997-05-31
EP0698389A1 (de) 1996-02-28
IL101758A (en) 1996-12-05
DE69215612T2 (de) 1997-05-15
EP0698389B1 (de) 1999-12-22
IL117356A (en) 2000-08-31
AU653048B2 (en) 1994-09-15
JP2000136149A (ja) 2000-05-16
KR100203339B1 (ko) 1999-06-15
JPH05148159A (ja) 1993-06-15
EP0531611B1 (de) 1996-12-04
IL117356A0 (en) 1996-07-23
DK0531611T3 (da) 1997-05-26

Similar Documents

Publication Publication Date Title
DE69215612T2 (de) Verzögerte Freigabe-Matrix für Arzneimittel
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
KR870005637A (ko) 약물 데포
DK0729357T3 (da) Mikroindkapslede 1,2-benzazoler
DK0605484T3 (da) Peptider med væksthormonfrigørende aktivitet
ES2090714T3 (es) Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.
HK1003978A1 (en) Composition for the treatment of schizophrenia
IL111519A (en) Sustained release tablets containing acetaminophen and methods for the preparation thereof
DK4481A (da) Hydroxyalkylstivelse som laegemiddelbaerer
SE8800025L (sv) Bioadhesiva farmaceutiska suppositoriepreparat
SE8703889L (sv) Farmaceutiska kompositioner med fordrojd frigoring
DE69232014D1 (de) Amethocain enthaltende Arzneimittel
SE8704240D0 (sv) Analgesic preparations
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
YU2394A (sh) Lizin so 6-hloro-5-fluoro-3-(-2-tenoil)-2-oksindol-1-karboksamida
KR870000071A (ko) 수의 운동을 개선하는 신규약제 조성물 및 그의 생산공정
MY110416A (en) Composition for the treatment of schizophrenia.
FR2628422B1 (fr) Le sel de sodium monohydrate de la 1,2- diphenyl-3,5-dioxo-4-n-butylpyrazolidine (" phenylbutazone ") et sa preparation
GT197640950A (es) Composiciones de oxitetraciclina y su preparacion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 698389

Country of ref document: EP